drugset / Trial / NCT01248468

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

NCT01248468

Phase 4 Completed 752 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.

Timeline

Start
2010-11
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 250 mg
Subject Aspirin Small molecule 250 mg
Subject Caffeine Small molecule 65 mg
Comparator Sumatriptan Unknown 100 mg

Indications